GeneDx Holdings Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	442.68	427.54	305.45	202.57	234.69	212.2
Revenue Growth (YoY)	34.09%	39.97%	50.79%	-13.69%	10.60%	18.33%
Cost of Revenue	134.77	129.37	111.05	112.56	261.44	228.8
Gross Profit	307.91	298.17	194.4	90.01	-26.75	-16.6
Selling, General & Admin	337.33	239.22	171.89	199.98	338.24	318.73
Research & Development	79.25	72.03	45.72	58.27	86.2	105.16
Other Operating Expenses	31.29	-	-	12.36	216.46	5.66
Total Operating Expenses	447.87	311.25	217.61	270.6	640.9	429.55
Operating Income	5.71	-13.08	-23.21	-180.6	-667.65	-446.15
Interest Income	-	-	-	-	-	0.08
Interest Expense	-	-	-	-	-	-2.84
Other Non-Operating Income (Expense)	-17.31	-8.06	-29.42	3.9	69.62	203.52
Total Non-Operating Income (Expense)	-11.48	-8.06	-29.42	3.9	69.62	200.76
Pretax Income	10.56	-21.14	-52.63	-176.69	-598.03	-245.39
Provision for Income Taxes	0.33	-0.12	-0.34	-0.93	-49.05	-
Net Income	10.81	-21.02	-52.29	-175.77	-548.98	-245.39
Net Income to Common	10.81	-21.02	-52.29	-175.77	-548.98	-245.39
Shares Outstanding (Basic)	29	29	27	24	10	3
Shares Outstanding (Diluted)	30	29	27	24	10	3
Shares Change (YoY)	6.10%	6.51%	10.61%	137.51%	212.56%	2106257.53%
EPS (Basic)	-2.66	-0.73	-1.94	-7.23	-53.63	-74.91
EPS (Diluted)	-2.68	-0.73	-1.94	-7.23	-53.63	-74.91
EBIT	5.71	-13.08	-23.21	-180.6	-667.65	-446.15

SEC Filings: 10-K · 10-Q